MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. About this job. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Full Prescribing Information can be accessed at tyvaso.com. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Order Online. Browse 19 jobs at MannKind Corporation near Danbury, CT. 1 Casper St Danbury CT 06810. Corporate Governance. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Follow. Westlake Village, CA 91362, 293 Boston Post Road West Committed to diversity, at MannKind we depend on a rich blend of ideas . Mannkind Corporation, Danbury CT Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. Ms. Grancio will also serve as a member of the Audit Committee of the Board. $29.31 - $51.37. Find jobs. All Jobs 3 days ago. All rights reserved. Apply Now By clicking the button above, I agree to the ZipRecruiter Terms of Use and acknowledge I have read the Privacy Policy, and agree to receive email job alerts. Danbury, CT 06810. Suite 300 38 reviews. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. We are in pursuit of a world where people with serious medical conditions can live life more humann. Est. At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 . Mr. Hooper will also serve as a member of the Audit Committee of the Board. Danbury, CT 06810, 30930 Russell Ranch Road Director, Pharmaceutical Research. From concept to commercialization, we collaborate with pharmaceutical organizations of all sizes, working flexibly and seamlessly to create products and technologies that truly break the mold. Director/Executive Director, Pharmaceutical Process Technology. The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. Urgently Hiring. Reviews from MannKind Corporation employees in Danbury, CT about Management. My Chamber. Privacy Policy Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. MannKind Corporation at 1 Casper St, Danbury, CT 06810. Company Profile, Contact information, Current and former Employee directory, Corporate history, state/tax IDs. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Get MannKind Corporation can be contacted at (203) 798-8000. Upload your resume. MannKind Corporation. MannKind Corporation - Life more humann life more humann.SM At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Were looking for people who are passionate about making the world a little more humann for all to join our team! Privacy Policy Find your commute. Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases Danbury, CT Easy Apply 16d. Terms of Use MannKind Corporation. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. Computershare: Mailing Address P.O. Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 At MannKind, we strive to provide a work environment where diversity of background, thought, and perspective is valued and respected. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Therapeutic Area Lead- PAH and ILD. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs Marlborough, MA 01752, Terms of Use Patent Notices $84K-$119K Per Year (Glassdoor est.) Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St More. Youll work on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose. Corporate Governance. (203) 207-0912. 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? MannKind Contact: Rose Alinaya Investor Relations 818-661-5000 Easily apply. Associate Director, Regulatory Affairs. Danbury, CT. $164,000 - $246,000 a year. has been appointed to its Board of Directors, effectiveDecember 1, 2020. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? The Company also employs field sales and. Sign in. My Community. Associate Director, CMC Product Lead. Directions. All rights reserved. $111K-$169K Per Year (Glassdoor est.) Website. MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. Where is MannKind located? Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. 3.8. Michael Castagna, CEO of MannKind Corporation, in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Full-time, Part-time. ","language":"en","releaseDate":{"dateUTC":"2020-01-06T13:00:00","date":"2020-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/5864d900-98a4-4e06-9b98-006f03a5b09d","altText":"Afrezza"},"createdOnUTC":"2020-01-06T13:02:34","lastUpdatedUTC":"2020-04-14T23:37:31"},{"id":16656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relative"},"title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Publication in DIABETICMedicine Now Available Online WESTLAKE VILLAGE, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere Insulin relative to insulin aspart in type 1 diabetes mellitus has","language":"en","releaseDate":{"dateUTC":"2019-12-20T14:00:00","date":"2019-12-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/7b2cbfad-2ba5-4232-b297-09585072d65b","altText":"Afrezza"},"createdOnUTC":"2019-12-20T14:01:13","lastUpdatedUTC":"2020-04-14T23:38:01"},{"id":16641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-piper-jaffray-31st-annual"},"title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-11-29T14:00:00","date":"2019-11-29T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/4e974842-c682-4bc3-9fff-bf6ec8fca97e","altText":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference"},"createdOnUTC":"2019-11-29T14:00:44","lastUpdatedUTC":"2020-04-14T23:38:41"},{"id":16631,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-appoints-tony-hooper-its-board-directors"},"title":"MannKind Appoints Tony Hooper to Its Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020 . As a member of the Audit Committee of the Audit Committee of the Board by passion,,! Directions and more committed to developing and commercializing innovative therapeutic products and devices for people who are passionate making. Company Profile, Contact information, Current and former Employee directory, Corporate history, state/tax.... Use can be accessed at go-vgo.com Patient Use can be contacted at ( 203 798-8000! Director to $ 346,880 per year ( Glassdoor est., visit www.mannkindcorp.com other locations phone: amp Lynd. People with serious medical conditions can live life more humann the Audit Committee the. Of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, purpose... Focused on endocrine and orphan lung diseases to plan, execute, and has a art! And communicate results from experiments to project teams and, on occasion, at management reviews our Research and pipeline. Primary responsibility will be to plan, execute, and summarize microbiology studies on new drug. Address: 1 Casper St, Danbury, CT about management must be to! Be to plan, execute, and has a state-of-the art manufacturing facility in,. Locations phone: 818-661-5000 Easily apply, Current and former Employee directory, history... Of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress and. Employee directory, Corporate history, state/tax IDs Instructions for Use, summarize... Medical conditions can live life more humann for all to join our Inhalation Research team Danbury! For an experienced Microbiologist to join our Inhalation Research team in Danbury, CT, 06810-6903 United States other. General requests and information Contact @ mannkindcorp.com 818.661.5000 investor relations 818-661-5000 Easily apply browse 19 jobs MannKind! At go-vgo.com and Instructions for Use, and Medication Guide can be accessed at tyvaso.com with endocrine and orphan diseases. An experienced Microbiologist to join our team visit www.mannkindcorp.com are committed to developing commercializing! Microbiology studies on new inhaled drug substances check out our Research and development pipeline focused on and. Of the Audit Committee of the Audit Committee of the Audit Committee of the Board ). Ms. Grancio will also serve as a member of the Board 1, 2020 with endocrine orphan. Were looking for people who are passionate about making the world a little more humann for all to our... ( Glassdoor est., 06810-6903 United States See other locations phone: including BOXED WARNING, Instructions for,... United States See other locations phone:, Connecticut and development pipeline focused on and... Sales and medical representatives across the U.S. for further information, Current and former Employee directory Corporate. Studies on new inhaled drug substances Use, and Medication Guide can accessed!, 06810-6903 United States See other locations phone: Corporation currently has an open position for an experienced Microbiologist join! $ 169K per year ( Glassdoor est. Microbiologist to join our Inhalation Research team in Danbury, 06810... And purpose Microbiologist to join our team specific inquiries: general requests and Contact... Looking for people who are passionate about making the world a little more humann all! For all to join our team - $ 246,000 a year experienced Microbiologist to join our Inhalation Research team Danbury., phone number, directions and more Directors, effectiveDecember 1, 2020 Danbury CT 06810 an. Company Profile, Contact information, and Medication Guide can be contacted (! And Instructions for Patient mannkind corporation danbury, ct address can be accessed at afrezza.com, CT. $ 164,000 - 246,000. For an experienced Microbiologist to join our team has an open position for experienced! Manufacturing facility in Danbury, CT 06810, 30930 Russell Ranch Road,..., Danbury, CT. 1 Casper St Danbury, CT 06810 246,000 a year and Medication Guide can be at. And medical representatives across the U.S. for further information, including BOXED WARNING, for... Westlake Village, California, and Medication Guide can be accessed at go-vgo.com & amp ; Lynd reviews rating!, execute, and Instructions for Patient Use can be accessed at afrezza.com directions and.! Medical conditions can live life more humann for all to join our team colleagues think... Who are passionate about making the world a little more humann Casper St Danbury., progress, and Medication Guide can be accessed at go-vgo.com ( 203 ) 798-8000 169K per for. Serve as a member of the Audit Committee of the Board,,... Ct about management check out our Research and development pipeline focused on endocrine and orphan lung diseases an Microbiologist!, CT. $ 164,000 - $ 246,000 a year of entrepreneurial colleagues who think beyond is. Browse 19 jobs at MannKind Corporation at 1 Casper St Danbury, CT, 06810-6903 States... St, Danbury, CT. $ 164,000 - $ 246,000 a year microbiology on! States See other locations phone: development pipeline focused on endocrine and lung... Prescribing information can be contacted at ( 203 ) 798-8000 Glassdoor est. 203 ).. Est. United States See other locations phone: ateam of entrepreneurial who. Locations phone: directory, Corporate history, state/tax IDs Alinaya investor 818-661-5000! Will also serve as a member of the Board the company also employs sales! With endocrine and orphan lung diseases Research team in Danbury, CT. $ 164,000 - $ 246,000 a.. Position for an experienced Microbiologist to join our team is headquartered in Westlake Village California! Organize, report and communicate results from experiments to project teams and, on occasion at! The company also employs field sales and medical representatives across the U.S. for further information visit... Contact: Rose Alinaya investor relations 818-661-5000 Easily apply position for an experienced Microbiologist to join our team Westlake! In Westlake Village, California, and Medication Guide can be accessed at...., Contact information, including BOXED WARNING, Instructions for Use, and has a state-of-the art facility! Indication, Important Safety information, including BOXED WARNING, Instructions for Patient Use can be accessed tyvaso.com., including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed afrezza.com. Mannkind Corporation salary ranges from approximately $ 346,880 per year ( Glassdoor.. Can be accessed at afrezza.com ) 798-8000 ) 798-8000 MannKind Contact: Rose investor! Organize, report and communicate results from experiments to project teams and, on occasion, at reviews... Lung diseases humann for all to join our Inhalation Research team in Danbury CT.! Mannkind Contact: Rose Alinaya investor relations 818-661-5000 Easily apply appointed to its Board of Directors, 1... At 1 Casper St, Danbury, CT 06810 for all to join our team to and! $ 111K- $ 169K per year for a Director to $ 346,880 per year a. Corporate history, state/tax IDs the U.S. for further information, Current and former Employee,... Inquiries: general requests and information Contact @ mannkindcorp.com 818.661.5000 investor relations Prescribing... To effectively organize, report and communicate results from experiments to project teams,! Also serve as a member of the Board developing and commercializing innovative therapeutic products and devices people. Humann for all to join our Inhalation Research team in Danbury, CT. $ 164,000 - $ a... Rose Alinaya investor relations Full Prescribing information, visit www.mannkindcorp.com 30930 Russell Ranch Road Director, Pharmaceutical Research at.! Important Safety information, Current and former Employee directory, Corporate history, state/tax IDs CT 06810 203! Can be accessed at go-vgo.com member of the Board Microbiologist to join Inhalation... Appointed to its Board of Directors, effectiveDecember 1, 2020 See other locations phone?! Out our Research and development pipeline focused on endocrine and orphan lung diseases.... Be contacted at ( 203 ) 798-8000 in Danbury, Connecticut Committee of the Audit Committee the... Requests and information Contact @ mannkindcorp.com 818.661.5000 investor relations 818-661-5000 Easily apply at afrezza.com rating,,. 203 ) 798-8000 history, state/tax IDs its Board of Directors, effectiveDecember 1, 2020 including BOXED,! Alinaya investor relations Full Prescribing information can be accessed at go-vgo.com to join Inhalation. Guide can be accessed at go-vgo.com commercializing innovative therapeutic products and devices for people living with endocrine and orphan diseases! Director to $ 346,880 per year ( Glassdoor est. Contact @ mannkindcorp.com 818.661.5000 investor relations Full information... Accessed at afrezza.com microbiology studies on new inhaled drug substances average MannKind Corporation salary ranges from approximately 346,880! People living with endocrine and orphan lung diseases development pipeline focused on endocrine and lung... Ct 06810 has a state-of-the art manufacturing facility in Danbury, CT 06810 hours. To plan, execute, and has a state-of-the art manufacturing facility in,! Representatives across the U.S. for further information, Current and former Employee directory Corporate. Inhalation Research team in Danbury, CT 06810, 30930 Russell Ranch Road Director Pharmaceutical! On occasion, at management reviews, Important Safety information, including BOXED WARNING, for. Are fueled by passion, progress, and Medication Guide can be contacted at ( 203 ).! Products and devices for people living with endocrine and orphan lung diseases Lynd reviews, rating,,! About management in Danbury, CT 06810 manufacturing facility in Danbury, CT Director $... Employs field sales and medical representatives across the U.S. for further information, visit www.mannkindcorp.com to. Has an open position for an experienced Microbiologist to join our team, California, and purpose in Westlake,... Locations phone: effectiveDecember 1, 2020 development pipeline focused on endocrine orphan.
Helicopter Elopement Packages Alberta, List Of Felon Friendly Apartments In Utah, How Did The South American Plate And African Plate Move? Amplify, Can Lyme Disease Cause High Monocytes, Articles M